Remdesivir was granted EUA from the FDA, based upon a 1000 patient study of "severe" covid-19, in which remdisivir group had 11.4% death rate and placebo group had 15.2% death rate. Data on severe only. Our s/c trial will also include critical cases, which should make our reduction of deaths a higher percentage than the above remdesivir study, leading to an EUA for leronlimab.